- Atlas
- Medicine & Health
- Psychopharmacology
Psychopharmacology
Psychopharmacology is the study of how drugs affect mood, thought, perception, and behaviour, and the branch of medicine that uses those drugs to treat mental illness.
17 frameworks, from 1900 to today · Mental Health · Medicine & Health
- Anxiolytic and sedative-hypnotic pharmacology 1900-Present
- Lithium and Mood Stabilization 1949-Present
- Serendipity-based clinical psychopharmacology 1949-1975
- Stimulant pharmacology for ADHD 1950-Present
- Neuroleptic and antipsychotic pharmacology 1952-Present
- Randomized controlled trial 1955-Present
- Anti-psychiatry 1960-1980
- Biological psychiatry 1960-Present
- Dopamine Hypothesis of Schizophrenia 1960-Present
- GABA-Benzodiazepine Anxiolytic Model 1960-Present
- Monoamine Hypothesis of Depression 1960-Present
- Mood Stabilizer Prophylaxis Model 1970-Present
- Receptor Pharmacology 1970-Present
- Biomarker and Precision Psychopharmacology 1985-Present
- Selective serotonin reuptake inhibitor 1987-2010
- Atypical antipsychotic 1989-Present
- Glutamate and Neuroplasticity Model 2000-Present
Overview
Psychopharmacology is the study of how drugs affect mood, thought, perception, and behaviour, and the branch of medicine that uses those drugs to treat mental illness. Its central question is deceptively simple: can a chemical change the mind in a way that relieves suffering? For most of medical history the answer was sought in sedatives and stimulants that altered consciousness broadly. Only in the 1950s did drugs arrive that seemed to act on specific symptoms of specific illnesses, and with them came a new way of thinking about mental disorder as a matter of brain chemistry. That shift reshaped psychiatry, emptied and refilled its hospitals, and created an industry. It also produced a long argument, still unresolved, about whether the drugs treat the causes of mental illness or only its surface, and about how much of their apparent success belongs to the pill and how much to the belief surrounding it.
Sedatives, Stimulants, and the Pre-Modern Pharmacopoeia
Before the mid-twentieth century, psychiatry had few drugs that targeted mental illness as such. It had sedatives: bromides from the nineteenth century, then barbiturates from around 1900, which calmed agitation and induced sleep but carried a narrow margin between sedation and death and a strong liability for dependence. It had opium and its derivatives for distress1. It had stimulants, including amphetamines from the 1930s, used for depression and fatigue23. And it had lithium salts, which had been used in the nineteenth century for gout and, in a few scattered reports, for mania; the Australian psychiatrist John Cade revived interest in 1949 when he found that lithium carbonate calmed guinea pigs and then manic patients. These were blunt instruments. They changed the state of the nervous system without any clear idea of which illness they addressed, and the dominant treatments for severe mental illness remained institutional, physical, and sometimes surgical: restraint, hydrotherapy, insulin coma, and lobotomy.
Chlorpromazine and the Birth of the Antipsychotic Era
The turning point came in 1952, when the French surgeons Henri Laborit, Jean Delay, and Pierre Deniker observed that chlorpromazine, a phenothiazine compound first developed as a surgical anaesthetic adjunct, produced a peculiar calm in psychotic patients without the heavy sedation of barbiturates. Patients with hallucinations and delusions became quieter, more accessible, and sometimes less deluded. The drug was marketed in the United States as Thorazine and spread rapidly through asylums. Its significance was not only clinical. Chlorpromazine appeared to act on the symptoms of schizophrenia specifically, which suggested that schizophrenia had a specific biology. Within a few years researchers found that the drug blocked dopamine receptors in the brain, and this observation became the foundation of the dopamine hypothesis of schizophrenia: the idea that psychotic symptoms arise from excessive dopamine activity, and that blocking dopamine relieves them. The hypothesis was supported by the parallel finding that amphetamines, which increase dopamine, could provoke a psychosis resembling schizophrenia.
The antipsychotic era transformed the asylum. Large numbers of long-stay patients could now be discharged or managed outside hospital, and the movement toward deinstitutionalisation gathered pace in the 1960s and 1970s. The drugs were not curative, and their side effects were serious: the "extrapyramidal" movement disorders, including the irreversible tardive dyskinesia, that came from prolonged dopamine blockade. But they gave psychiatry its first widely effective pharmacological tool and made the brain-chemistry model of mental illness credible to a profession that had been dominated by psychoanalysis.
The Monoamine Hypothesis and the Antidepressants
A second wave of discovery followed in the late 1950s. Iproniazid, an antituberculosis drug, was found to elevate mood, and it worked by inhibiting monoamine oxidase, an enzyme that breaks down neurotransmitters45. Imipramine, a compound related to chlorpromazine, proved effective against depression without the sedation of the antipsychotics. These findings, together with the observation that reserpine (a blood-pressure drug) depleted monoamines and could cause depression, produced the monoamine hypothesis: the proposal that depression results from a deficiency of monoamines—serotonin, noradrenaline, and dopamine—in the brain, and that drugs which raise their levels relieve it. The hypothesis was a powerful organising idea. It gave depression a biological story and guided the search for better drugs.
That search produced the selective serotonin reuptake inhibitors4. The first, fluoxetine (Prozac), reached the market in 1987, followed by sertraline, paroxetine, and others. These drugs blocked the reuptake of serotonin specifically, with fewer of the side effects of the older tricyclics, and they were heavily marketed to a public newly willing to discuss depression. Their arrival coincided with a broad expansion of antidepressant prescribing, and the SSRIs became the emblem of a pharmacological approach to ordinary unhappiness as well as clinical depression. The monoamine hypothesis, meanwhile, came under strain: drugs raised monoamine levels within hours, but therapeutic benefit took weeks, and many patients did not respond at all. The simple deficiency story could not account for this, and later research turned toward downstream changes in receptor sensitivity and neural plasticity.
Lithium and the Mood Stabilisers
Lithium occupies a distinctive place. Cade's 1949 report was followed by controlled trials in the 1950s and 1960s, and by the 1970s lithium was established as the first drug with a specific preventive action in bipolar disorder, reducing both manic and depressive relapses. Its mechanism was long obscure—it affects several signalling pathways—and its narrow therapeutic window required regular blood monitoring, which limited its use. But it demonstrated that a mental illness could be managed prophylactically over years, and it became the model for the mood-stabiliser class, later joined by anticonvulsants such as valproate and carbamazepine.
Benzodiazepines and the Anxiolytic Model
Anxiety had its own pharmacological revolution. The barbiturates were dangerous, and in the late 1950s Leo Sternbach at Hoffmann-La Roche developed chlordiazepoxide, marketed in 1960 as Librium, followed by diazepam (Valium) in 1963. The benzodiazepines acted on a specific receptor site associated with the inhibitory neurotransmitter GABA, producing calm and sleep with a much wider safety margin than the barbiturates. They were prescribed in enormous quantities through the 1960s and 1970s, and the benzodiazepine receptor became one of the best-characterised sites in neuropharmacology. The subsequent recognition of dependence and withdrawal led to tighter prescribing, but the class remains in use for short-term anxiety and for specific indications.
Receptor Pharmacology and the Atypical Antipsychotics
Through the 1970s and 1980s, psychopharmacology became increasingly a science of receptors1. The identification of distinct dopamine receptor subtypes (D1 and D2, later D3–D5) and of multiple serotonin receptor families allowed drugs to be designed for particular targets. Clozapine, introduced in Europe in the 1970s, was the prototype of the "atypical" antipsychotics: it caused fewer movement side effects than the older drugs and seemed to help patients who had not responded to them, though it carried a risk of a dangerous blood disorder, agranulocytosis, requiring regular blood counts67. Its success, and that of risperidone and olanzapine in the 1990s, was attributed to a combination of dopamine and serotonin blockade, and the atypical class largely displaced the older drugs. The claim that atypicals were more effective for negative symptoms and cognition was later questioned by large comparative trials, but the class reshaped prescribing and the economics of the field.
Clinical Trials and the Evidence Problem
As the drug arsenal grew, so did the machinery for testing it. The randomised controlled trial, in which patients are assigned by chance to drug or placebo, became the standard method, and the double-blind design—neither patient nor assessor knowing who received which—was meant to remove bias. The trials that established chlorpromazine, lithium, and the antidepressants were landmarks of this method. But the method also revealed a persistent puzzle: in many antidepressant trials the drug outperformed placebo only modestly, and the placebo response itself was large and growing. This raised the question of how much of the drugs' effect was pharmacological and how much was expectation, and it fed a long-running debate about the size of the true benefit.
Anti-Psychiatry and the Critique of the Drug Model
The rise of drug treatment provoked a counter-movement. In the 1960s and 1970s, figures associated with anti-psychiatry—R8. D. Laing, David Cooper, and Thomas Szasz, though their positions differed sharply—argued that mental illness was not a brain disease to be medicated but a response to social conditions, a label applied to deviance, or a problem of living. Szasz's The Myth of Mental Illness (1961) attacked the very concept of mental illness as disease; Laing's work on schizophrenia emphasised its existential meaning. The critique was not primarily pharmacological, but it challenged the premise on which psychopharmacology rested: that mental disorders are biological entities that drugs can correct. The movement's influence on mainstream psychiatry faded, but its questions about coercion, labelling, and the limits of the medical model persisted and shaped later debates about over-prescription and patient consent.
Neuroimaging and the Search for Biomarkers
From the 1980s onward, new tools let researchers look at the living brain. Positron emission tomography and, later, functional magnetic resonance imaging allowed the measurement of receptor occupancy, blood flow, and metabolic activity in patients and in volunteers given drugs. These methods confirmed, for example, that antipsychotic doses occupying a certain proportion of D2 receptors were associated with both benefit and side effects, and they supported the idea that different illnesses involve different neural circuits. The hope was that imaging, genetics, and other biomarkers would allow treatment to be matched to the individual patient—"personalised" or "precision" psychopharmacology—rather than prescribed by trial and error. Progress has been slower than hoped: no blood test or scan yet reliably predicts which antidepressant will work for a given person, and the field still relies heavily on clinical judgment and sequential trials.
The Present: A Field of Effective but Imperfect Tools
Contemporary psychopharmacology rests on the classes built in the postwar decades: antipsychotics, antidepressants, mood stabilisers, anxiolytics, and stimulants for attention disorders. Their mechanisms are understood in far more detail than in 1952, and prescribing is guided by a large body of controlled trials and by guidelines that weigh efficacy against side effects. The monoamine hypothesis has been revised rather than abandoned, and research now focuses on glutamate, neuroplasticity, and the immune and endocrine systems as additional contributors9. Newer agents, including ketamine and its derivatives for treatment-resistant depression, have shown rapid effects that the older drugs could not, and have reopened the question of how antidepressants actually work. The field's open problems are substantial: the modest advantage of many drugs over placebo, the difficulty of predicting response, the side-effect burden of long-term treatment, and the unresolved relationship between the biology of mental illness and the social conditions in which it arises. The drugs changed what psychiatry could do; they did not settle what mental illness is.
References
- Psychopharmacology (Modern psychopharmacology), Wikipedia
- Management of attention deficit hyperactivity disorder (History), Wikipedia
- Stimulant, Wikipedia
- Anxiolytic (History), Wikipedia
- Monoamine oxidase inhibitor (History), Wikipedia
- Atypical antipsychotic (History), Wikipedia
- Clozapine (introduction, History), Wikipedia
- Anti-psychiatry, Wikipedia
- Pharmacology of antidepressants, Wikipedia
The frameworks of Psychopharmacology
Each framework is a way of working the field has used: when it held, and the question it answers.
- 1900-Present
Anxiolytic and sedative-hypnotic pharmacology
How do sedatives calm the nervous system?
- 1949-Present
- 1949-1975
Serendipity-based clinical psychopharmacology
Can chance observations yield psychiatric drugs?
- 1950-Present
- 1952-Present
Neuroleptic and antipsychotic pharmacology
How do drugs relieve psychosis?
- 1955-Present
- 1960-1980
- 1960-Present
- 1960-Present
Dopamine Hypothesis of Schizophrenia
Does excess dopamine cause psychosis?
- 1960-Present
GABA-Benzodiazepine Anxiolytic Model
How does GABA inhibition produce calm?
- 1960-Present
- 1970-Present
- 1970-Present
- 1985-Present
Biomarker and Precision Psychopharmacology
Can biomarkers guide drug choice?
- 1987-2010
Selective serotonin reuptake inhibitor
Do SSRIs specifically treat depression?
- 1989-Present
- 2000-Present
Glutamate and Neuroplasticity Model
Does neuroplasticity explain antidepressant action?
How the ideas connect
Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.
Mood Stabilizer Prophylaxis Model grew out of Lithium and Mood Stabilization
Lithium's demonstrated ability to prevent manic and depressive relapses became the model for the mood-stabilizer class. The prophylaxis model was generalized to anticonvulsants such as valproate and carbamazepine.
Neuroleptic and antipsychotic pharmacology influenced by Serendipity-based clinical psychopharmacology
The serendipitous observation that chlorpromazine calmed psychotic patients without heavy sedation, made by Laborit, Delay and Deniker, opened the antipsychotic era. That clinical finding, not a prior theory, launched the systematic use of neuroleptics.
Carried by Henri Laborit; Jean Delay; Pierre Deniker.
Monoamine Hypothesis of Depression influenced by Serendipity-based clinical psychopharmacology
The chance observations that iproniazid elevated mood and imipramine relieved depression, together with reserpine-induced depression, supplied the clinical facts from which the monoamine hypothesis was built. The hypothesis was an attempt to explain these serendipitous drug effects.
Carried by Nathan Kline; Roland Kuhn.
Dopamine Hypothesis of Schizophrenia influenced by Neuroleptic and antipsychotic pharmacology
The discovery that antipsychotic drugs block dopamine receptors, together with the finding that amphetamines provoke a schizophrenia-like psychosis, led directly to the dopamine hypothesis. The drug mechanism was the empirical basis for the theory.
Carried by Arvid Carlsson; Jacques Van Rossum.
Atypical antipsychotic grew out of Neuroleptic and antipsychotic pharmacology
Atypical antipsychotics were developed as an improvement on the older neuroleptics, aiming to reduce extrapyramidal side effects while retaining antipsychotic efficacy. Clozapine served as the prototype, and risperidone and olanzapine followed in the 1990s.
Carried by Clozapine; Risperidone; Olanzapine.
Selective serotonin reuptake inhibitor grew out of Monoamine Hypothesis of Depression
The monoamine hypothesis, and specifically the idea that serotonin deficiency underlies depression, motivated the search for drugs that selectively block serotonin reuptake. Fluoxetine and the other SSRIs were the direct product of that search.
Carried by Fluoxetine.
Atypical antipsychotic influenced by Receptor Pharmacology
Receptor pharmacology identified distinct dopamine and serotonin receptor subtypes, allowing drugs to be designed for particular targets. The atypical antipsychotics were explicitly developed on this basis, combining D2 and 5-HT2A blockade.
Lithium and Mood Stabilization influenced by Randomized controlled trial
The randomized controlled trial became the standard method for testing lithium's prophylactic action in bipolar disorder. The controlled trials of the 1950s and 1960s that established lithium as a mood stabilizer used this design.
Carried by Mogens Schou.
Selective serotonin reuptake inhibitor influenced by Randomized controlled trial
The randomized controlled trial, with double-blind assessment, was the method by which the SSRIs were tested and approved. The trials also revealed the modest advantage over placebo that shaped later debate.
Biological psychiatry rival of Anti-psychiatry
Anti-psychiatry attacked the biological and drug-treatment model of mental illness, arguing that schizophrenia was a label imposed by society. Biological psychiatry defined itself in opposition to this critique, reasserting a brain-based account of disorder.
Carried by Thomas Szasz; R. D. Laing.
Biomarker and Precision Psychopharmacology grew out of Biological psychiatry
Biological psychiatry's program of grounding mental illness in brain biology led to the search for biomarkers that could guide diagnosis and drug choice. Biomarker and precision psychopharmacology is the later, more targeted form of that program.
Atypical antipsychotic influenced by Dopamine Hypothesis of Schizophrenia
The dopamine hypothesis, and the identification of dopamine receptor subtypes, guided the design of atypical antipsychotics that combined dopamine and serotonin blockade. The theory provided the rationale for the new drugs' target profile.
Glutamate and Neuroplasticity Model replaced Monoamine Hypothesis of Depression
The monoamine hypothesis could not explain the delayed therapeutic action of antidepressants or the many non-responders. The glutamate and neuroplasticity model replaced it as the leading explanation, focusing on downstream changes in synaptic plasticity.
Biomarker and Precision Psychopharmacology influenced by Monoamine Hypothesis of Depression
The monoamine hypothesis suggested that measures of monoamine function might predict drug response, encouraging the search for biomarkers. That search later became the precision psychopharmacology program.
Glutamate and Neuroplasticity Model influenced by Selective serotonin reuptake inhibitor
The clinical limitations of SSRIs, including delayed onset and incomplete response, helped drive the search for glutamatergic and plasticity-based explanations. The rapid antidepressant effects of ketamine then supported the new model.
Beyond the field
Where Psychopharmacology's ideas came from in other fields, and what they led to there: the strongest 12 of 60 links.
Stimulant pharmacology for ADHD influenced Pediatric Psychopharmacology in Child And Adolescent Psychiatry
Stimulant pharmacology for ADHD, from Bradley's benzedrine observations through methylphenidate trials, is the founding strand of pediatric psychopharmacology. The controlled trials and dosing practices developed for hyperactive children became the model for the field.
Carried by Charles Bradley.
Randomized controlled trial influenced by Clinical Pharmacology and Controlled Therapeutic Trials in Translational Pharmacology
Controlled therapeutic trial methodology, crystallized in the 1948 streptomycin trial, supplied the randomization and control procedures that the psychiatric randomized controlled trial adopted.
Carried by Austin Bradford Hill.
Biological psychiatry influenced Pediatric Psychopharmacology in Child And Adolescent Psychiatry
Biological psychiatry's neurotransmitter and receptor theories, and its randomized drug trials, supplied the rationale and methods that pediatric psychopharmacology applied to children. The shift to treating childhood disorders with drugs followed directly from this model.
Dopamine Hypothesis of Schizophrenia influenced by Neurotransmitter-System Pharmacology in Neuroscience
The dopamine hypothesis rests on neurotransmitter-system pharmacology: the finding that antipsychotic potency tracks dopamine-receptor blockade, argued by Carlsson and Lindqvist in 1963 and by van Rossum in 1966.
Carried by Arvid Carlsson; Jacques van Rossum.
Monoamine Hypothesis of Depression influenced by Neurotransmitter-System Pharmacology in Neuroscience
The monoamine hypothesis was framed in neurotransmitter-system terms, drawing on reserpine-induced depression and the amine-reuptake actions of tricyclics described by Schildkraut and Bunney in the mid-1960s.
Carried by Joseph Schildkraut; Neurotransmitter-System Pharmacology (1950).
Biomarker and Precision Psychopharmacology influenced by Pharmacogenetics and Pharmacogenomics in Pharmacology
Pharmacogenetics, from the 1950s work on inherited drug-metabolism differences, is the direct ancestor of the genetic stratification used in precision psychopharmacology. Metaboliser phenotyping and genotype-guided dosing carried over into psychiatry.
Biomarker and Precision Psychopharmacology influenced by Pharmacogenomics in Translational Pharmacology
Pharmacogenomics supplied the central biomarker logic of precision psychopharmacology: CYP2D6 and CYP2C19 metaboliser status and HLA variants used to predict antidepressant and antipsychotic response and adverse effects. The genotyping methods and variant-to-dose reasoning passed directly into psychiatric practice.
Selective serotonin reuptake inhibitor influenced by Neurotransmitter-System Pharmacology in Neuroscience
Neurotransmitter-system pharmacology established serotonin reuptake as a target and supplied the assays and transporter concepts used to screen for selective inhibitors. The SSRI class was built by applying that framework to serotonin specifically.
Carried by Arvid Carlsson.
Selective serotonin reuptake inhibitor grew out of Psychopharmacology in Psychiatry
The SSRI class emerged directly from psychiatric psychopharmacology: the serotonin hypothesis of depression and the tricyclic experience motivated the search for selective serotonin reuptake inhibitors, culminating in fluoxetine's approval in 1987. The class is a branch of that parent enterprise.
Carried by Fluoxetine (1987).
Atypical antipsychotic influenced by Neurotransmitter-System Pharmacology in Neuroscience
Neurotransmitter-system pharmacology supplied the serotonin-dopamine interaction concepts and receptor-binding assays that defined the atypical profile of clozapine and its successors. The class was designed and justified using that framework.
Atypical antipsychotic grew out of Psychopharmacology in Psychiatry
Atypical antipsychotics arose within psychiatric psychopharmacology as a refinement of the dopamine hypothesis: clozapine's low extrapyramidal liability was explained by combined D2 and 5-HT2A blockade, and the class was developed on that basis. It is a branch of the parent discipline.
Carried by Clozapine.
Anxiolytic and sedative-hypnotic pharmacology influenced by Inhalation Anesthesia in Anesthesiology
Inhalation anesthesia established the clinical practice of titrating volatile central depressants to a reversible level of consciousness, and the barbiturate and sedative-hypnotic tradition adopted the same dose-titration logic for intravenous and oral hypnotics.

Psychopharmacology is a planet in Nousfarer
Its city has a tower for each of these 17 frameworks. Land, walk in, and climb one concept at a time.
Land on PsychopharmacologyRelated fields
Fields its ideas are linked to
- Psychiatry 9 links
- Neuroscience 8 links
- Pharmacology 5 links
- Mental Health 4 links
- Child And Adolescent Psychiatry 3 links
- Pharmacodynamics 3 links
- Translational Pharmacology 3 links
- Medicinal Chemistry 2 links
- Neurology 2 links
- Neuropsychology 2 links
- Anesthesiology 2 links
- Health Policy Evaluation 1 link
More in Mental Health
- Addiction Science
- Child And Adolescent Psychiatry
- Community Mental Health
- Developmental Psychopathology
- Forensic Psychiatry
- Mental Health
- Mental Health Policy And Systems
- Psychiatry
- Psychopathology
- Psychotherapy
See where Psychopharmacology sits on the Map of Human Knowledge